1

A Perspective on Oversight of API Manufacturing Sites

Albinus D’Sa, Ph.D.Deputy Country Director India Office U.S. Food and Drug Administration

Department of Health and Human Services

Indian Pharmaceutical Association 2012, Mumbai, July 12-13, 2012

2

Current US Pharmaceutical Industry Landscape• Increased generic drug demand

– Increase in median age of population– Innovator patents expiring– Downward cost pressure from payers

• More outsourcing and globalization of finished dosage manufacturing – Specialization in facets of upstream manufacturing

• API manufacturing is an example of a 40-year trend in outsourcing to specialists culminating by shift away from domestic (in this case specialty chemical) manufacturing base

Manufacturers will gain competitive edge through high quality and superior management of supply chains

3

Registration StatisticsRegistered Domestic and Foreign Establishments

as of FY2012 3rd Quarter

44%

36%

3%

17%

domestic manufacturer

foreign manufacturer

domestic API Manufacturer

foreign API Manufacturer

”Manufacturers” exclude API manufacturers as well as contract sterilization, analytical labs, PET, repackaging/packaging, labeling/relabeling

4

Foreign GMP InspectionsAll Drugs

0

50

100

150

200

250

300

350

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

GMP

PAI GMP

GMP China

PAI GMP China

5

Drug Inspections in India

2008 2009 2010 2011 2012

6

Quality Problems Traced to Supply Chain are Driving a Heightened Focus on

Ingredient Manufacturing

• API – Highest Expectations for GMP• Excipients• Dietary supplement ingredients• Food ingredients • Cosmetic ingredients

Higher Quality Standards for Ingredients

7

Examples of Recalls Traced to ExcipientVariability or Low Levels of Impurities

• Four recalls in 2010 due to dissolution failure were ascribed to excipients– Aldehyde impurity (OTC drug)– Properties of Zein (OTC drug)– Intra-batch variability in Ethylcellulose used in

MR coating in capsule formulation (2 events involving the same product)

– Acid value of Glyceryl Behenate matrix carrier in a microsphere formulation

8

FDA Detects High Levels of Peroxide in Imported Crospovidone and Issued a Drug Safety Advisory

10/21/2010http://www.fda.gov/drugs/drugsafety/ucm230492.htm

• Peroxide levels found (1700 ppm) were 30-40x typical levels in this excipient

• Peroxides can degrade APIs resulting in sub-potent drug• Impurity levels were not being monitored by the

manufacturer of Crospovidone• Certificates of analysis were not indicating presence of

such high levels of peroxide• USP to revise monograph to add limit of peroxide

9

Observation: Manufacturers are Applying High Standards for Ingredient Quality Assurance

• More intensive supplier qualification by finished product manufacturers– Auditing of ingredient manufacturing sites– Expectations for direct communication

between makers and user of ingredients– More rigor in standards of quality for

ingredients– More frequent user confirmatory testing

10

FDA API CGMP Inspections• API - ingredient intended to furnish pharmacologic effect• The law defines API as a drug because it is a component

of a drug• The law requires all drugs to be manufactured in

conformance with CGMP– API not manufactured in conformance with CGMP is

deemed adulterated– An import alert can be issued when an API appears to

be adulterated as a result of inspection findings• ICH Q7 is a standard for FDA inspection of API

establishment (see also CDER Compliance Program Guidance Manual section 7356.002F)

11

• CGMP inspections– Focused on six systems

• Quality management system is always inspected• Facilities and equipment, Materials, Production,

Packaging and Labeling, Laboratory• On a pre-approval inspection FDA will also be looking at

the control of the API manufacturing process with greatest emphasis on critical process parameters and quality attributes

• Biotechnologically derived APIs– Are usually going to be produced as “Sterile API”– Other more rigorous inspection programs which apply finished

dosage form CGMP will generally apply

FDA API Pre-approval and CGMP Inspection Programs

12

Facilities and Equipment Systems• Risks to address

– Cross contamination risk– Contamination due to equipment or exposure of API

process– Mix-ups

------------------------------------------------------------------------------• Facility and equipment design

– Flow of materials, people, activity– Cleaning during changeovers– Compatibility of materials with process stream– Identification of each piece of equipment and piping

systems• Maintenance

13

Areas of High Contamination Risk• Dry processing such as drying or particle

size reduction can generate airborne fine particles

• Equipment which if not properly maintained or taken out of service when in irreversible disrepair can shed particles

• Areas in which there is potential for API to accumulate and not be readily removed during cleaning

14

Materials Systems• Identification and purity specifications and

testing of critical starting materials• Segregation in warehouse to avoid mix-ups• Tracking of inventory and traceability

– traceability of API starting materials– FDA is particularly concerned about agriculturally

derived starting materials• Water quality

– Minimum standard is WHO drinking water quality– Water purification systems should be validated– Water quality should be monitored and controlled

using action limits and procedures to describe actions taken when limits are exceeded

15

Suppliers of Critical Raw Materials for API Manufacturing

• System for technical evaluation of suitability• System for approval of suppliers by the QU• Agreed upon purchasing specification• Name and address of the manufacturer of the

critical raw material known• Written agreement to be notified about

significant changes to manufacturing that might impact critical material quality

16

API Guidance Which Cover Starting Materials

ICH Q7A: GMP Guidance for APIhttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073497.pdfICH Q11: Draft Guidance on Development and Manufacture of Drug Substanceshttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM261078.pdfDraft Guidance on Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Qualityhttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291390.pdf

Total – deficiencies seen on API inspections 2007-2010, by region

0%

5%

10%

15%

20%

25%

CONT

AMIN

ATIO

NDE

VIAT

ION

FRO

M D

MF/

ND

A...

BUI

LDIN

GS/

FAC

ILIT

IES

EQUI

PMEN

T DE

SIG

N, S

IZE

, LO

CA

EQ

UIP

ME

NT C

LEAN

ING

/MA

I...

CONT

ROL

CO

MPO

NEN

TS, I

NTE

RM

PRO

DU

CTIO

N/PR

OC

ESS

CO

NTRO

INA

DEQ

UAT

E VA

LID

ATIO

N P

RO

TOP

ACKA

GIN

G/L

ABE

LIN

GST

ABIL

ITY

PR

OG

RAM

H

OLD

ING

/DIS

TRIB

UTI

ON

CO

...IN

ADE

QUA

TE L

AB

CO

NTR

OLS

UN

VALI

DAT

ED L

AB T

EST

M...

DEFI

CIEN

CIES

IN R

ECO

RDS.

..RE

PRO

CES

SIN

G/R

EW

ORK

SC

ONT

ROL

OF

WA

TER

SY

ST...

DEF

ICIE

NCI

ES IN

ME

DIA

FILL

SIN

ADE

QU

ATE

PRO

CES

S VA

LID

ATLA

CK

OF/

INA

DEQ

UAT

E S

OP

S

QA

SYS

TEM

S

SYST

EM Q

UAL

IFIC

ATIO

NC

OM

PUTE

R V

ALID

ATIO

N IN

ADEQ

UATE

CO

MPL

AINT

I...

OR

GAN

IZA

TIO

N/P

ERS

ON

NEL

IN

ADE

QU

ATE

ENVI

RONM

ENTA

L C

All Europe India China

Source: DIDQ CO reviews of EIRs as reported in CMS

Date of data pull: Sept 19, 2011

Buildings/Facilities

Equipm

ent d

esign, 

Size, location

Equipm

ent cleaning/

Maintenance 

Raw M

aterial Controls

Productio

n/Process

Control

Inadequate Lab Controls

Invalidated Lab Test 

Methods

Inadequate SOPS

QA System

sSystem

 Qualifications

Buildings/Facilities

Equipm

ent d

esign, 

Size, location

Equipm

ent cleaning/

Maintenance 

Productio

n/Process

Control

Control Com

ponents, 

Interm

ediates,

Raw M

aterials

Invalidated Lab Test 

Methods

Inadequate SOPS

QA System

s

System

 Qualifications

Equipm

ent cleaning/

Maintenance 

Productio

n/Process

Control

Invalidated Lab Test 

Methods

Inadequate SOPS

QA System

s

System

 Qualifications

Control Com

ponents, 

Interm

ediates,

Raw M

aterials

Equipm

ent d

esign, 

Size, location

Equipm

ent cleaning/

Maintenance 

Productio

n/Process

Control

Control Com

ponents, 

Interm

ediates,

Raw M

aterials

Invalidated Lab Test 

Methods

Inadequate SOPS

QA System

s

System

 Qualifications

22

Lab Systems - Data Integrity• Accurate and reliable data and information• Ensuring data trustworthiness and reliability, as

related to the security of the information/data• Quality

– the degree to which a collection of data is complete, consistent, and accurate.

• Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA)– FDA may look to see that the process of data

creation at the site can be reconstructed and that it matches the information submitted to the agency. If problems are discovered, the integrity of the data is questionable.

23

Data Integrity – What We See• Not recording activities contemporaneously

– Backdating• Fabricating data

– Copying existing data as new data• Discarding data

– Not saving electronic or hard copy data• Discarding data to release failing product

– Repeat sampling or testing until compliance can be documented

24

Loss of Data Integrity - Observations• Batch production record

– 7 instances involving 2 employees signing as having completed manufacturing steps; neither employee was on the premises at the time the steps were completed

• Stability– Testing conducted late but recorded as having been

tested on time– Testing data was generated without samples having

been taken• Analytical Method Validation

– Results from the method validation of one drug were used for the method validation of another drug

25

Loss of Data Integrity - Observations• Test Data for Batch Release

– Test results for one batch were used to release other batches• Occurred for at least 3 batches• Happened at two unrelated firms

– Employee used same sample for identity testing of multiple batches

– Firm repackaged and released failing batch without performing an investigation

26

Data Integrity - References

• FDA’s Guidance to Industry: Part 11, Electronic Records; Electronic Signatures — Scope and Application, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070295.pdf

• Glossary of Computer Systems Software Development Terminology (8/95), available athttp://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074875.htm

27

Nine FDA Warning Letters Were Issued to Foreign API Manufacturers in 2011

• Failure to conduct adequate release testing• Failure to investigate failing lab results• Failure to validate analytical methods• Lab control issues and falsification of lab data• Failure to review data before release and failure to

evaluate suppliers• Failure to implement procedures to prevent cross-

contamination with penicillin products• Failure to document manufacturing operation records

and inadequate facilities• Inadequate production records and laboratory controls• Failure to investigate deviations and inadequate

maintenance

28

Validation• All API manufacturing processes should be

validated– FDA recommends a lifecycle approach to validation

• All test methods for release of API should be validated

• All test methods should be suitable and scientifically sound for intended purpose– In process testing– Testing of starting materials, reagents, solvents,

catalysts, etc.

29

Residual Solvents and Metallic Impurities

• API manufacturers should be prepared to provide identity of potential residual solvents and metallic impurities to finished dosage form manufacturers– Requirements apply to finished drug products– See ICH Q3C for residual solvents (Option 2)– ICH Q3D (soon to be a Step 2 draft) and draft USP

chapters <231> and <232> express impending expectations for metallic impurities

• Instrumental methods to replace heavy metals test• Calculation of metallic impurities in drug products will usually

be based on levels in APIs and excipients

30

Expect To See More…• Inspections of foreign API sites

– Heightened focus on inspections related to generic drug manufacturing

– More focus on management of suppliers• Consistent raw materials fit for purpose• Integrity of API supply chains

• Sharing of information with trusted regulatory counterparts under confidentiality agreements

• 3rd party involvement, especially in supplier audits normally conducted by finished drug manufacturers

31

References• Validation

–FDA Guidance on Process Validation: General Principles and Practiceshttp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070336.pdf

• Residual Solvents –ICH Q3C

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073394.pdf–USP <467>

• Elemental (Metallic) Impurities USP <232>–USP-PF 37(3)

32

Acknowledgements• Karan Takahashi• Grace McNally• Raphael Brykman• Steven Wolfgang

33

albinus.dsa@fda.hhs.gov

+91 9650 4982 30

NDBoxFDAIndia@State.gov